These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23282234)

  • 21. Molecular mechanisms of renal allograft fibrosis.
    Waller JR; Nicholson ML
    Br J Surg; 2001 Nov; 88(11):1429-41. PubMed ID: 11683737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic renal allograft rejection: pathophysiologic considerations.
    Joosten SA; Sijpkens YW; van Kooten C; Paul LC
    Kidney Int; 2005 Jul; 68(1):1-13. PubMed ID: 15954891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pathology of chronic allograft dysfunction.
    Racusen LC; Regele H
    Kidney Int Suppl; 2010 Dec; (119):S27-32. PubMed ID: 21116314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive immunohistological analysis of the endothelin system in human kidney grafts.
    Frank K; Zeier M; Gross ML; Waldherr R; Ritz E; Amann K
    Nephrol Dial Transplant; 2006 May; 21(5):1365-72. PubMed ID: 16449275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplant hypertension and chronic renal allograft failure.
    Paul LC; Benediktsson H
    Kidney Int Suppl; 1995 Dec; 52():S34-7. PubMed ID: 8587280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of chronic renal allograft dysfunction in a rat model with complete and exclusive MHC incompatibility.
    Poehnert D; Broecker V; Mengel M; Nashan B; Koch M
    Transpl Immunol; 2010 Feb; 22(3-4):137-43. PubMed ID: 19815070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations.
    Chapman JR
    Kidney Int Suppl; 2005 Dec; (99):S108-12. PubMed ID: 16336561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histology and proteinuria after renal transplantation.
    Serón D; Burgos D; Alonso A
    Transplant Rev (Orlando); 2012 Jan; 26(1):20-6. PubMed ID: 22137728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic rejection of rat renal allograft. I. Histological differentiation between chronic rejection and cyclosporin nephrotoxicity.
    Yilmaz S; Taskinen E; Paavonen T; Mennander A; Häyry P
    Transpl Int; 1992 May; 5(2):85-95. PubMed ID: 1627245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapy strategies in the prevention of chronic allograft nephropathy].
    Scolari MP; Cappuccilli ML; Comai G; Piccari M; Ortolani M; Conte D; Lanci N; Bianchi F; Todeschini P; Campieri C; Stefoni S
    G Ital Nefrol; 2005; 22 Suppl 31():S36-40. PubMed ID: 15786400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rejection and function and chronic allograft dysfunction.
    de Fijter JW
    Kidney Int Suppl; 2010 Dec; (119):S38-41. PubMed ID: 21116316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged cold ischemia accelerates cellular and humoral chronic rejection in a rat model of kidney allotransplantation.
    Solini S; Aiello S; Cassis P; Scudeletti P; Azzollini N; Mister M; Rocchetta F; Abbate M; Pereira RL; Noris M
    Transpl Int; 2012 Mar; 25(3):347-56. PubMed ID: 22239163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic allograft nephropathy: current concepts and future directions.
    Nankivell BJ; Chapman JR
    Transplantation; 2006 Mar; 81(5):643-54. PubMed ID: 16534463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Non-immunological risk factors associated with chronic allograft nephropathy following kidney transplantation].
    Shiroki R; Hoshinaga K
    Hinyokika Kiyo; 2002 Nov; 48(11):693-7. PubMed ID: 12512144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.1 Differential diagnosis of chronic graft dysfunction.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():4-8. PubMed ID: 12091617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
    Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.